Show simple item record

dc.contributor.authorDoebele, R. C.
dc.contributor.authorPerez, L.
dc.contributor.authorTrinh, H.
dc.contributor.authorMartinec, M.
dc.contributor.authorMartina, R.
dc.contributor.authorRiehl, T.
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorMeropol, N. J.
dc.contributor.authorWong, W B
dc.contributor.authorCrane, G.
dc.date.accessioned2021-09-07T13:16:17Z
dc.date.available2021-09-07T13:16:17Z
dc.date.issued2021en
dc.identifier.citationDoebele RC, Perez L, Trinh H, Martinec M, Martina R, Riehl T, et al. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. Journal of Comparative Effectiveness Research. 2021 Aug 24.en
dc.identifier.pmid34427452en
dc.identifier.doi10.2217/cer-2021-0131en
dc.identifier.urihttp://hdl.handle.net/10541/624535
dc.description.abstractAim: Generating direct comparative evidence in prospective randomized trials is difficult for rare diseases. Real-world cohorts may supplement control populations. Methods: Entrectinib-treated adults with advanced ROS1 fusion-positive NSCLC (n = 94) from Phase I/II trials (ALKA-372-001 [EudraCT2012-00148-88], STARTRK-1 [NCT02097810], and STARTRK-2 [NCT02568267]) were compared with a real-world crizotinib-treated cohort (n = 65). Primary end point, time-to-treatment discontinuation (TTD); secondary end points, PFS and OS. Results: Median (95% CI) weighted TTD: 12.9 (9.9-17.4) months for entrectinib; 8.8 (6.2-9.9) months for crizotinib (weighted hazard ratio, 0.72 [0.51-1.02]). Median OS with entrectinib was not reached, weighted median OS with crizotinib was 18.5 (15.1-19.9) months. Conclusion: Entrectinib administered in clinical trials may be associated with longer TTD than a real-world crizotinib population.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.2217/cer-2021-0131en
dc.titleComparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLCen
dc.typeArticleen
dc.contributor.departmentAnschutz Medical Campus, University of Colorado, 1665 Aurora Court Anschutz Cancer Pavilion, Aurora, CO 80045, USAen
dc.identifier.journalJournal of Comparative Effectiveness Researchen
dc.description.noteen]
refterms.dateFOA2021-09-08T13:19:17Z


Files in this item

Thumbnail
Name:
34427452.pdf
Size:
1.125Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record